Drug Profile
Research programme: tissue factor antagonists - Novo Nordisk/Sunol Molecular Corporation
Latest Information Update: 08 May 2008
Price :
$50
*
At a glance
- Originator Sunol Molecular Corporation
- Class Small molecules
- Mechanism of Action Thromboplastin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 05 Mar 2003 This programme is still in active development
- 29 Nov 1999 Preclinical development for Cardiovascular disorders in Denmark (Unknown route)